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Hyperlipidemia is reemerging as an important cardiovascular disease risk factor and other
metabolic disorders, such as obesity, insulin resistance and type-2 diabetes. Hepatic de
novo lipogenesis is controlled by a family of the b-zip transcription factors, the sterol
regulatory element-binding proteins (SREBPs), which targets downstream genes
involved in free fatty acids, triglycerides and cholesterol synthesis. Regulation of
SREBPs signaling is controlled by a cluster of the ER membrane-bound proteins, the
insulin induced gene-1(Insig-1) and gene-2 (Insig-2) and the SCAP protein. The cAMP
responsive element binding protein H (CREBH) is a recently identified member of this
family. CREBH is selectively and highly expressed in the liver and small intestine which
is actively involved in lipid and glucose metabolism. However, its underlying molecular
mechanisms are not fully understood. Here we demonstrated CREBH inhibits hepatic
lipid de novo synthesis through modulating the expression of insulin induced gene-2
(Insig-2) isoform-a, a liver specific isoform of Insig-2, which is involved in the activation
of sterol regulatory element-binding proteins (SREBPs). Metabolic cues, such as fasting,
glucagon and cAMP agonist, activated CREBH which in turn inhibited SREBP-1c and
SREBP-2 activation via upregulate the abundance of Insig-2a in hepatocytes. Depletion
or suppression of CREBH expression by refeeding inhibited Insig-2a expression, which
in turn hyperactivated SREBP-1c and -2, leading to the activation of hepatic de novo

lipid synthesis, accumulation of lipids in hepatocytes and systemic hyperlipidemia. We
further demonstrated that depletion of CREBH reduced both mRNA and protein
expression of apolipoprotein B (apoB). In vitro, transient expression of CREBH cDNAs
in McA cells induced significant increase of apoB mRNA and protein expression, which
indicated the positive regulatory impact of CREBH on apoB biosynthesis. This study
establishes the CREBH-Insig-2a as a novel metabolic pathway that regulates hepatic de
novo lipogenesis. This novel finding provides new mechanistic insight into the
pathogenesis of hyperlipidemia in metabolic diseases.

i

Acknowledgements

The rewarding experience of attending UNL was only matched by the important
relationships and wealth of knowledge that I gained during that time. I would first like to
thank my supervisor, Dr. Qiaozhu Su, for the guidance, support, tolerance, and
opportunities, as well as my committee members, Dr. Timothy Carr and Dr. Julie
Albrecht, for their guidance and advice throughout my studies. I especially thank Julie for
her laughs and hugs. Also, I would like to thank Vicky Samek, Sara Frendick, Katherine
A. Pinkerton, and Molly Weiss from the animal facility for all their kind help and advice.
Next, I would like to thank all the lab members, past and present, for their support –
Patricia Christian, Hai Wang, Tongxue Dong, and Jing Shen. Especially to Patricia, a
respected friend, who was a constant source of understanding, encouragement, and great
advice as I worked to complete my research, thesis and course work. I would also like to
thank Mengna, Wei, Dandan, Jing, Inhae, Meshail, Liz, Tovah, Joe, Yong, Rio, Daniel
and all other lab members for their generous help of this research work as well as my life
in Lincoln. Finally, big thanks to the office faculty, Lori Rausch, Lori Beals, and Ann
Grasmick for all their kind help.
All my family members and friends- I love you all more than you will ever know.
Finally, thank you to The Department of Nutrition and Human Health at The University
of Nebraska - Lincoln.

ii

Table of Contents
Acknowledgements .............................................................................................................i
Table ontents.......................................................................................................................ii
List of bbreviations.............................................................................................................iv
Chapter I
General introduction.......................................................................................................1
1.1 Obesity and hyperlipidemia......................................................................................1
1.2 Lipid and lipoprotein metabolism.............................................................................4
2.1 Lipids.................................................................................................................4
2.2 Lipoprotein metabolism.....................................................................................4
1.3 ER stress and ER-bound proteins............................................................................12
1.4 Metainflammation...................................................................................................17
1.5 Study aims...............................................................................................................20
Chapter II
Materials and Methods.................................................................................................21
2.1 Cell culture and reagents........................................................................................21
2.2 Animals and animal experimental protocols..........................................................22
2.3 Immunoblots analysis.............................................................................................23
2.4 mRNA analysis by real-time PCR.........................................................................25
2.5 Quantification of hepatic TG.................................................................................26
2.6 Statistical analysis..................................................................................................26
Chapter III
Results..........................................................................................................................27

iii

Chapter IV
Disscussion...................................................................................................................46
Chapter V
References....................................................................................................................51
Chapter VI
Appendix......................................................................................................................57

iv

List of Abbreviations
FA

fatty acid

apoB

apolipoprotein B

VLDL

very-low-density-lipoprotein

CM

chylomicron

IDL

intermediate-density-lipoprotein

LDL

low-density-lipoprotein

LDLR

LDL-receptor

HDL

high-density-lipoprotein

LPL

lipoprotein lipase

apoA-I

apolipoprotein A-I

ChIP

chromatin immunoprecipitation

DGAT-1

diacylglycerol acyltransferase-1

DGAT-2

diacylglycerol acyltransferase-2

ERAD

ER-associated degradation

FBS

fetal bovine serum

DMEM

Dulbecco’s Modified Eagle Medium

DMSO

dimethyl sulfoxide

NC

negative control

PBS

phosphate buffer saline

BSA

bovine serum albumin

Tris

tris (hydroxymethyl) aminomethane

SDS

sodium dodecyl sulfate

v

SDS-PAGE

SDS-polyacrylamide gel electrophoresis

PVDF

polyvinylidene fluoride

TBST

1x Tris-buffered saline with tween

HRP

horseradish peroxidase

TEMED

N, N, N’, N’,-tetramethylethylenediamine

ANOVA

two-way analysis of variation

SREBP

sterol regulatory element-binding protein

SR-BI

scavenger receptor class B type 1

MTP

microsomal triglyceride transfer protein

HCL

hydrochloric acid

NaCl

sodium chloride

EDTA

ethylenediaminetetraacetic acid

EGTA

ethylene glycol tetraacetic acid

McA

McA-RH 7777 cells

WT

wild type

KO

knockout

1

Chapter one
General Introduction
1.1 Obesity and Hyperlipidemia
Obesity is often defined simply as a condition of abnormal or excessive fat accumulation
in adipose tissue, which usually leads to health impairments1,2. According to the current
worldwide statistical data from the WHO, at least 2.8 million people die each year
because of being overweight or obese, and overweight or obesity leads to an estimated
35.8 million (2.3%) of global Disability-Adjusted Life Years. In the United States, two
thirds of adults are obese or overweight, and thirty-six percent of US adults are obese.
This places a heavy burden on public health care because many cannot lose sufficient
weight to improve their health with lifestyle interventions alone3. The emergence of
overweight and obesity as the predominant challenges to global health is undisputed, and
obesity rates are highly correlated with many incurable diseases4,5.

Over several decades, research has elucidated that overweight and obesity have adverse
metabolic effects on blood pressure, cholesterol, and triglycerides, and can lead to
dyslipidemia, glucose intolerance, and insulin resistance, and even increased risk of some
cancers, including breast, colon, prostate, kidney, and gall bladder3,6,7,8. In summary,
morbidity and mortality rates increase with the prevalence of obesity, which has been a
great health burden for the world2,6. Despite the wealth of information gathered over the
last several decades about lipid metabolism and its relevant-diseases, the mechanisms
connecting them are not yet fully understood 2,9.
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Obesity is a commonly acknowledged risk factor for various metabolic disorders or
diseases, and people with abdominal obesity are more inclined to have hyperlipidemia,
which is widely recognized as one of the main co-morbidities in obesity10,11.
Hyperlipidemia indicates abnormally elevated levels of one or more lipids and/or
lipoproteins in the blood, and elevated levels of low-density-lipoprotein is the most
common form of hyperlipidemia12. In the United States, it is estimated that more than
thirty percent of the adult population suffers from hyperlipidemia13. Hyperlipidemia can
lead to excess lipids in the arteries, which is a risk factor for the development of
atherosclerosis and CVD7,14; there is also strong evidence showing a link between lipid
abnormalities and CVD14,15. Hyperlipidemia progresses in association with obesity, type
2 diabetes, and other metabolic abnormalities, including hypertension and non-alcoholic
fatty liver diseases (NAFLD), together referred to as the “metabolic syndrome”, which is
a great threat to human health in the 21st century10,11,15. Moreover, hyperlipidemia and its
relevant complications exact tremendous economic burden on public health sources6.
Hyperlipidemia and/or excess lipid accumulation can initiate a low-grade and chronic
inflammatory response in adipose tissue, which is a causative factor of insulin
resistance12. Hyperlipidemia can also result in the activation of the unfolded protein
response and mitochondrial dysfunction, which can further trigger metabolic
inflammation13. Metabolic inflammation may then lead to macrophage recruitment,
which could increase adipose tissue lipolysis, leading to excess lipid delivery and ectopic
lipid accumulation. This would further lead to impairments in insulin signaling and
contribute to insulin resistance16. Therefore, a vicious cycle occurs between lipid
metabolism and inflammation. To our knowledge, though many genetic and
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environmental factors have been shown to be involved in the process of hyperlipidemia,
the mechanism of hyperlipidemia is still not clearly known15,17.
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1.2 Lipid and lipoprotein metabolism
1.2.1 Lipids
Lipids constitute a wide group of naturally occurring molecules that include fats, waxes, sterols,
fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides,
triglycerides, phospholipids, and others. The main biological functions of lipids include storing
energy, signaling, and acting as structural components of cell membranes. The property that sets
lipids apart from other major nutrients is their solubility in organic solvents such as ether,
chloroform, and acetone. All lipids are hydrophobic and mostly insoluble in blood, so they
require transport within hydrophilic, spherical structures called lipoproteins.
Structurally, lipoproteins consist of two parts with a single layer of phospholipid and cholesterol
molecules on their outside, surrounding a central core of lipids. Since the polar part of each
phospholipid faces out, the outside of the lipoprotein particle is polar and therefore compatible
with the surrounding water environment. On the other hand, the nonpolar portion of each
phospholipid faces inward, and thus is compatible with the very nonpolar ingredients of the core
of the lipoprotein. The nonpolar lipid core includes mainly triacylglycerol and cholesteryl ester.
Lipoproteins also possess surface proteins (called apoproteins or apolipoproteins) that are
cofactors and ligands for lipid-processing.

1.2.2 Lipoprotein metabolism
Lipoprotein fractions can be classified as chylomicron (CM), very-low-density lipoprotein
(VLDL), low-density lipoprotein (LDL), or high-density lipoprotein (HDL) according to the
ratio of lipid to protein within the particle as well as the different proportions of lipid typestriacylglycerol, cholesterol, cholesteryl esters, and phospholipids. Such differences influence the
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density of the particle, which has become the physical characteristic used to differentiate and
classify the various lipoproteins18,19. Table 1 summarizes several physical and chemical
characteristics of the human lipoproteins.
Apolipoproteins, the protein components of lipoproteins, tend to stabilize the lipoproteins as they
circulate in the aqueous environment of the blood, but they also have other essential roles 19,20. In
addition, apolipoproteins confer specificity on the lipoprotein complexes, allowing them to be
recognized by their specific receptors19. A partial listing of the apolipoproteins, the lipoproteins
with which they are associated, and their postulated physical functions, is listed in Table 2.
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Table.1. Major classes of human plasma lipoproteins: some properties
(Adapted from Lehninger Principles of Biochemistry 6th edition)

Chylomicrons

VLDL

LDL

HDL

Density (g/mL)

< 0.95

0.95-1.006

1.019-1.063

1.063-1.225

Diameter (Å)

1,000-10,000

300-800

200-250

50-120

Apolipoprotein
constituents

apoB48
apoA-I
apoA-II
apoA-IV
apoC-I
apoC-II
apoC-III
apoE

apoB100
apoA-I
apoA-II
apoA-IV
apoC-I
apoC-II
apoC-III
apoE

apoB100

apoA-I
apoA-II
apoA-IV
apoC-I
apoC-II
apoC-III
apoE

Protein (wt %)

2

10

23

55

Triglycerides

85

50

10

4
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Table. 2. Apolipoproteins of the human plasma lipoproteins
(Adapted from Lehninger Principles of Biochemistry 6th edition)

Apolipoprotein

Lipoprotein association

Function (if known)

ApoA-I

HDL

Activates LCAT; interacts with ABC
transporter

ApoA-II

HDL

Inhibits LCAT

ApoA-IV

CMs, HDL

Activates LCAT; cholesterol
transport/clearance

ApoB48

CMs

Cholesterol transport/clearance

ApoB100

VLDL,LDL

Binds to LDL receptor

ApoC-I

VLDL,HDL

ApoC-II

CMs, VLDL, HDL

Activates lipoprotein lipase

ApoC-III

CMs, VLDL, HDL

Inhibits lipoprotein lipase

ApoD

HDL

ApoE

CMs, VLDL, HDL

Triggers clearance of VLDL and CM
remnants
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Chylomicrons (CMs) are the primary form of lipoprotein formed from exogenous or dietary
lipids, and they are responsible for the transport of dietary lipids into the circulation. Enterocytes
of the intestine resynthesize triacylglycerides, and together with phospholipids, cholesterol, and
apolipoprotein 48 (apoB48) (human) or apoB100 (rodents), assemble them into CMs. CMs are
secreted into the lymph and reach the plasma through the thoracic duct21,22. Once the CMs reach
peripheral tissues, lipoprotein lipase (LPL) will hydrolyze their triacylglycerides; the products –
fatty acids (FA) – then enter cells. The remaining smaller particles are called chylomicron
remnants, which acquire some cholesterol esters from HDL21 (see below). The change in particle
size also uncovers apoE, which mediates the remnant binding to the apoB/E receptor and to the
LRP in the liver21.
Lipoproteins other than CMs transport endogenous lipids, which are circulating lipids that do not
arise directly from intestinal absorption and are instead processed though other tissues, such as
liver, muscle and adipose tissue. Triglyceride-rich VLDL is synthesized and secreted from the
liver, a process that requires apoB100. In plasma, the triglyceride in VLDL is broken down into
free FA and glycerol by LPL and its cofactor, apolipoprotein C-2 (apoC-2). Through this
lipolysis, VLDL rapidly loses much of its triglyceride and becomes IDL, which will be further
hydrolyzed and turn into LDL. Through the action of the LDL receptor, LDL is cleared from the
plasma.
Alteration in hepatic lipoprotein secretion can induce disorders in lipid metabolism and an
imbalance between lipogenesis and lipoprotein assembly can lead to many diseases, including,
but not limited to hypertriglyceridemia, hepatic steatosis, cardiovascular diseases, and diabetes.
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Liver
Intestine
Capillaries
VLDL

CMs

LDL

IDL

Fig.1a. Lipoprotein metabolism schematics. Lipoproteins are like little vehicles that carry and
transport fat from one part of the body to the next. CMs are produced in the cells of the intestines
and carry fat that has been digested in the intestines into the body via the lymphatic system.
VLDL is a carrier for fat that has been produced in the liver. LDL is derived from VLDL and
IDL is the intermediate product of VLDL conversion to LDL. LDL is mainly sent back to the
liver and its contents recycled.

10

Fig.1b. Schematic diagram of LDL and its only structural protein apo100. The figure illustrates
the proposed organization of apoB-100 on the LDL particle surface: blue, β structure; red, αhelical structure; darker blue and red, structures on the front of the sphere; lighter blue and red,
structures on the back of the sphere. Adapted from JP Segrest, et al. 2001, J lipid Research.
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1.2.3 Very-low-density lipoprotein (VLDL) and apolipoprotein B (apoB)
ApoB100 is the main structural protein of VLDL; both are synthesized in the lumen of the rough
endoplasmic reticulum (ER) and secreted from the liver. Endogenous triglycerides,
phospholipids, cholesterol, and cholesteryl esters can be transported in VLDL particles to
peripheral tissues and organs, such as adipose tissue, muscles, and heart. The biogenesis of
VLDL and its secretion into the circulatory system by the liver plays an essential role in lipid
homeostasis since a major portion of triglycerides synthesized de novo is used for the formation
of VLDL. Triglyceride in the ER appears to manage the intracellular fate of newly synthesized
apoB100 protein because higher lipid levels can protect apoB from degradation. ApoB protein,
expressed in the liver and intestine, has two forms: apoB100 and apoB48. In the human liver,
only apoB100 is translated, whereas in the mouse liver, both forms are translated. ApoB is
nonexchangeable (it never leaves the VLDL particle), which makes it an ideal indicator of
VLDL production18. Emerging evidence has shown that high levels of lipids in the liver can lead
to apoB accumulation and cause ER stress23,24,25.
ApoB serves as the basic scaffolding upon which TG-rich lipoproteins, VLDL and chylomicrons,
and cholesterol-rich LDL are assembled (Fig. 1b.)26. Each lipoprotein particle contains just one
apoB molecule. Full-length apoB, apoB100, one of the largest known proteins, is synthesized in
the liver as a 4536-amino acid polypeptide (550 kDa)26. Through an RNA editing event that
converts the Gln2153 codon to a stop codon, a truncated form (apoB48) containing 48% of the
protein from the N-terminal is produced from the same RNA. In human, the RNA editing event
only occurs in the intestine but not in the liver27. Thus, human CMs carry apoB48 whereas
VLDL and LDL carry apoB100. In some rodents, including mice and rats, both forms of apoB
are produced in the liver.
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1.3 ER dysfunction and ER-resident proteins

1.3.1 ER dysfunction
The ER is the major site in the cell responsible for synthesis of lipids and sterols, as well as
protein folding, maturation, quality control, and trafficking. The ER also plays important roles in
stress response and cell metabolism. Specifically, in response to several stress stimuli, ERtransmembrane signaling molecules, including nuclear receptors, transcription factors, and
cellular enzymes, can regulate lipid metabolism and/or glucose biosynthesis28,29,30. Accumulation
of misfolded or unfolded proteins in ER induces ER stress and results in refolding or degradation
of the proteins, which is termed unfolded protein response (UPR)29,31. The UPR signaling
network has been shown to involve three core elements: PKR-like ER kinase (PERK), activating
transcription factor 6 (ATF6), and inositol-requiring protein-1 (IRE1). Activation of these three
pathways of the UPR leads to translation arrest and degradation of misfolded proteins, the
expression of ER molecular chaperones, and the expansion of the ER membrane to decrease the
load of proteins and increase the protein-folding capacity in the ER. UPR signaling was
originally described as a system to evade cellular damage in acute ER perturbation32. However,
more recent advances have revealed that UPR signaling provides important signals for regulating
cellular physiology28,31. In summary, UPR signaling functions to restore and maintain
homeostasis in the ER or to induce apoptosis if ER stress remains unmitigated. Recent studies
implicate hepatic ER stress as a central abnormality associated with the development of
metabolic syndrome, obesity, hepatic insulin resistance, and hepatic steatosis33,34. However, the
exact mechanisms remain obscure and treating obesity-related diseases by focusing on mitigating
ER stress deserves further investigation.
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1.3.2 SREBPs
Sterol regulatory element binding proteins (SREBPs), a family of ER membrane-binding
transcription factors, mainly mediate lipid homeostasis by regulating the expression of a range of
lipogenic genes, which are highly involved in the balance of endogenous cholesterol, FA, and
triacylglycerol synthesis35,36,37. The three main SREBP isoforms, SREBP-1a, SREBP-1c, and
SREBP-2, have different essential roles in lipid synthesis38. Recent transgenic and knockout (KO)
mice studies indicate that SREBP-1c is particularly involved in FA synthesis and insulin-induced
glucose metabolism (in lipogenesis), whereas SREBP-2 is more specific to cholesterogenic gene
synthesis; the SREBP-1a isoform seems to be implicated in both pathways38,39.
Structurally, SREBPs consist of four domains with two membrane-spanning regions, and they
function depending on the alteration of their structure. Initially, SREBPs are synthetized as
approximately 120kDa inactive precursors that are bound to the ER membrane. When sterol is
deprived, SREBPs translocate into the Golgi, escorted by SREBP cleavage-activating protein
(SCAP), and this process requires cleavage by two distinct proteases in the Golgi apparatus.
Finally, the SREBP precursors are cleaved by a sequential two-step cleavage process to release
the NH (2)-terminal active domain (nuclear SREBP, roughly 70kDa) into the nucleus to activate
their target genes, which are mainly involved in cholesterol and FA synthesis36. It has been
established that SCAP functions as a cholesterol sensor and is required for cleavage of SREBPs.
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NH2

NH2

COOH

COOH

Cytosol
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p
Lumen of ER

NH2
Nucleus
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Fig.2. SREBPs function as a control for lipid synthesis. SREBPs play a key role in
transcriptional regulation of cholesterol metabolism in response to cholesterol levels in the cell.
When cholesterol is abundant in the cell, the SREBPs are retained in the ER. When cholesterol
levels decrease, SREBPs are cleaved and released to act as transcription factors, binding to the
promoters of genes such as the LDL receptor and HMG CoA Synthase. The SREBPs are cleaved
and activated by two proteases in the Golgi apparatus, S1P (Site 1 protease) and S2P (Site 2
protease). S1P cleaves the SREBP region and S2P cleaves in the transmembrane region of
SREBPs. Regulation by sterols is provided by SCAP. SCAP activates S1P when sterols are low,
inducing SREBP activation, and does not activate S1P when sterol levels increase.
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1.3.3 Insulin induced genes (Insigs)
Insigs are also ER-resident proteins that contain six transmembrane segments that are highly
involved in lipid synthesis40,41. As mentioned before, SREBPs and SCAP together form a
complex and then move into the Golgi to activate lipogenesis genes. However, if Insigs combine
with this complex, this transportation will be obstructed and therefore reduce lipid synthesis. In
other words, when cellular cholesterol levels are high, Insigs proteins bind and trap SCAP,
retaining it in the ER and preventing it from escorting SREBPs from the ER to the site of
proteolytic activation in the Golgi complex. Therefore, the INSIG-SCAP-SREBP pathway plays
a crucial role in the feedback regulation of lipid metabolism and may be an intriguing factor in
obesity development.
Research shows that Insigs include two closely related membrane proteins Insig-1 and Insig-2,
known for their function as a promoter for ER retention of SCAP, and negative regulation of
SCAP and HMG-CoA reductase42,43,44. Though both Insig-1 and Insig-2 can principally regulate
cholesterol feedback, they show some distinct differences. Firstly, though Insig-2 protein has 59%
amino-acid sequence identity to Insig-1, Insig-2 performs a divergent role in regulating
cholesterol homeostasis. Another important distinction is that high expression level of Insig-1
can retain the SCAP–SREBP complex in ER, even when sterols are completely depleted.
However, Insig-2 requires that at least some sterols be present. Moreover, they are inversely
regulated by insulin in the liver. Specifically, when insulin decreases upon fasting, Insig-1
expression also decreases, while Insig-2 expression increases. On the other hand, in refed
animals, rising insulin levels promotes downregulation of Insig-2 and upregulation of Insig-143,45.
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It has been reported that Insig-2 has two isoforms: a liver-specific transcript of Insig-2,
designated Insig-2a, and another transcript designated Insig-2b. They arise through the use of
different promoters that produce different noncoding first exons that splice into a common
second exon46,44. Although the Insig-2a and -2b mRNAs encode identical proteins, they differ in
patterns of regulation. Insig-2a is the predominant transcript in the liver of fed animals, and it is
selectively down-regulated by insulin. Insig-2a mRNA increases when mice are fasted, and it
declines when they are refed. The transcript also increases in the liver of rats whose insulinsecreting pancreatic beta cells have been destroyed by streptozotocin, and it is reduced when
insulin is injected. The insulin-mediated fall in Insig-2a may allow SREBP-1c to be processed,
thereby allowing insulin to stimulate FA synthesis, even under conditions in which hepatic
cholesterol levels are elevated.

1.3.4 CREBH
Cyclic AMP-responsive element-binding protein H (CREBH, encoded by the gene CREB3L3) is
a recently found ER-bound bZiP transcription factor that is highly and specifically expressed in
the liver and the small intestine47,48. CREBH is activated and then processed in the Golgi
apparatus by proteolytic cleavage of the transmembrane domain by S1P and S2P proteases,
which release the N-terminal portion of the protein that enters the nucleus to act as a
transcription factor49. In the nucleus, activated CREBH binds to cAMP response elements (CRE)
and activates transcription driven by CRE-containing promoters, such as the rat
phosphoenolpyruvate carboxykinase promoter. The expression of CREBH is dependent on
hepatocyte nuclear factor 4α, which is a nuclear hormone receptor that is necessary for initiating
and maintaining hepatocyte differentiation and liver function49. Originally, CREBH was
estimated to be activated by ER stress in a manner analogous to that of the canonical UPR
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pathway initiator-ATF650. However, subsequent independent studies demonstrated that ER stress
failed to induce the proteolytic activation of CREBH, which further questioned the hypothesis
that CREBH is involved in the ER stress response51. A novel study showed that CREBH
processing is not increased by ER stress in CREBH KO mice C57BL/6 control mice.
CREBH is structurally and functionally related to the SREBPs52. Recent studies have shown that
CREBH is actively involved in lipid metabolism, and can be activated by free FA, fasting,
inflammatory cytokines, and peroxisome proliferator activated receptor α (PPARα)

53,50,54,55

.

Depletion of CREBH causes hyperlipidemia and severe NAFLD upon high-fat diet in rodent
models50. Recent studies also showed that fenofibrate decreases hepatic lipid synthesis through
induction of CREBH, which behaves as a novel negative regulator of SREBP-1c production and
hepatic lipogenesis56. However, the underlying molecular mechanisms for the action of CREBH
in lipid metabolism and the development of NAFLD still remain unknown. Thus, accumulating
evidence suggests a potential link between hepatic ER stress and drug-induced fatality; however,
the function of the ER stress protein CREBH, which is highly expressed in the liver, has not yet
been extensively studied.

1.4 Metainflammation
1.4.1 Metainflammation
The association between lipid accumulation and metainflammation is widely acknowledged57.
Metainflammation was first introduced by Gokan Hotamisligil from the Harvard School of
Public Health, and he used the term “metainflammation” to describe this state of low-grade
inflammation, which leads to inflammatory response in many tissues and has been postulated to
play an important role in many metabolic abnormalities like insulin resistance, type 2 diabetes,
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and NAFLD58,59,60. Hyperlipidemia can initiate metainflammation in adipose tissue, which
results in insulin resistance61,62,63Metainflammation may further trigger lipid abnormalities
Therefore, a vicious cycle occurs between lipid metabolism and inflammation. The strong and
consistent relationships between makers of inflammation and risk of CVD have been confirmed
by both epidemiological and clinical studies64,65,66,67. Inflammatory mechanisms can lead to
atherosclerosis through underlying pathophysiological mechanisms, and TNFα has been
implicated in this process as an inflammatory cytokine68,69. However, the exact mechanism is
still unclear.
1.4.2 TNFα
Emerging evidence has accumulated over the past several decades that inflammation is
implicated in lipid abnormalities70,71. A major proinflammatory cytokine, TNFα, has been
implicated in this process. Specifically, TNF is a critical cytokine, highly involved in both
physiological and pathological processes. The TNF family is made up of many members with
various roles, including TNF alpha (TNFα), TNF beta (TNFβ), CD40 ligand (CD40L), and Fas
ligand (FasL). TNF-α plays a critical role in the pathogenesis of both acute and chronic
inflammatory diseases by binding two ubiquitously expressed membrane receptors: p55 (TNF
receptor 1) and p75 (TNF receptor 2)72,73. TNFα has been found to be involved in the regulation
of several biological processes in liver, muscle and adipose tissue, including but not limited to
immune-inflammatory and lipid homeostasis. Intraperitoneal injection of TNFα into C57B6 mice
leads to an obvious accumulation of fat in the liver74,75. In addition, administration of TNFα can
rapidly increase serum triglyceride and triglyceride-rich lipoprotein levels in diabetic rats76.
TNFα can also stimulate significant expression and function of the LDL receptor77. Furthermore,
many studies have revealed that TNFα can directly block tyrosine phosphorylation of insulin
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receptor and interfere with insulin signal transduction, leading to decreased insulin sensitivity78,79.
It has also been shown that TNFα can induce ER stress53,80,81 and ER stress can also induce the
activation of CREBH53,82. Specifically, TNFα can prompt CREBH mRNA expression in a timedependent manner53. Meanwhile, increased TNFα can directly stimulate hepatic assembly and
secretion of VLDL. However, it is unknown whether or not TNFα regulates apoB levels by
altering the expression of CREBH.
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1.6 StudyAims
Specific Aim 1:
Determine the impact of CREBH signaling via insig 2a on hepatic lipogenesis and systemic
hyperlipidemia. We will use Western blots to measure the relevant protein levels, including
CREBH, Insig-1, Insig-2, and SREBPs. At the same time, we also plan to measure mRNA levels
of CREBH, Insigs, SREBPs, and several SREBPs target genes.

Specific Aim 2:
Determine the impact of CREBH signaling on hepatic VLDL secretion via apoB expression.
Firstly, we will determine whether overexpression of CREBH in McA-RH 7777 (McA) cells
induces mRNA and protein expressions of ApoB. Next, we will test if overexpression of apoB
induced by TNFα is capable of reducing hepatic lipid load to rescue CREBH-null mice from
TNFα-induced CREBH expression.
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Chapter Two
Materials and Methods
1. Cell culture and reagents
1.1 Cell lines and cell culture conditions
Rat hepatoma McA cells and human hepatoma HepG2 cells were cultured in 5% CO2 at 37°C in
Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Inc. -BRL, Grand Island, NY)
supplemented with 10% or 5% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 100 units/ml
penicillin/streptomycin (Invitrogen, San Diego, CA). Equal numbers of cells were seeded onto
tissue culture plates (60–mm culture dish). When cell confluence reached approximately 60%,
the cells were subjected to serum starvation for 12 h in medium without FBS and treated as
indicated below. Cells were subsequently processed for the isolation of RNA and protein.
1.2 Transfections
Transient transfections of cells with mammalian expression vectors were performed using
Lipofectamine (Life Technologies, Grand Island, NY) according to the manufacturer's
instructions. Briefly, 0.5×106 McA cells were plated in each well of a 6-well plate the day before
transfection. The next day, 2 µg of DNA was first diluted in 100 µl serum-free medium followed
by the addition of 8 µl Lipofectamine reagent. This mixture was then mixed well and incubated
at room temperature (RT) for 20 minutes. During this time, 12 µl of Lipofectamine reagent was
diluted in another 100 µl of serum-free medium per sample. At the end of 20-minute incubation,
the diluted Lipofectamine reagent was added to the DNA mixture and incubated at RT for
another 20 minutes. During this time, cells were deprived of serum supplements and incubated in
1.5 ml serum-free medium. At the end of the second 15-minute incubation, the
DNA/Lipofectamine mixture was gently mixed into each well of a 6-cm plate of cells. The cells
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were then incubated at 37°C for 5 hours, then 2 ml of medium supplemented with 10% FBS was
added to each plate. The plates were then incubated at 37°C for 24 hours before further
treatments.
1.3 Reagents
Forskolin (TOCRIS, Bristol, United Kingdom) was dissolved in Dimethyl sulfoxide (DMSO) to
a final concentration of 10 mM. Glucagon (EMD4 Biosciences, Millipore, MA) was dissolved in
5% Acetic Acid to a final concentration of 1mg/ml, and the final working solution is 1µg/ml.
Recombinant human TNF-a (Life technologies, Grand Island, NY) was dissolved in saline to a
final concentration of 10µg/ml. Poloxamer (Sigma-Aldrich Canada Ltd., Oakville, ON) was
dissolved in saline to have a 20% solution. The pH of each solution was adjusted to 6.8–7.4, and
each solution was freshly prepared on the day of use.
2. Animals and animal experimental protocols
C57BL/6J mice were obtained from Jackson Laboratory, Maine, US. Mice were fed a standard
chow diet containing 13.2% fat, 24.6% protein, and 62.1% carbohydrate (kcal/100 kcal) (#5053,
Lab Diet). Heterozygous CREBH mice were kindly provided by Dr. Zhang Kezhong as a gift.
Mice were housed in a 12 hours light/dark cycle with ad libitum access to food and water and
euthanized by isoflurane. Both male and female mice around 2 months old were used in each
experiment.
For some experiments, both wild type (WT) and CREBH KO mice were divided into fasted and
refed groups. The fasted group was fasted 13 hours with free access to water and anesthetized
under isoflurane. At the same time, the refed group was also fasted for 13 hours with free access
to water and then fed an ad libitum diet for 8 hours before sacrifice. A baseline fasting blood
sample was obtained from the submandibular vein. In Olive oil gavage treatment, mice were
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fasted overnight for 5 hours with free access to water, followed a baseline fasting blood sample
was collected and Poloxamer 407 was administrated 2.5ul/g by ip injection. Both WT and
CREBH KO mice were fed 200µl virgin olive oil (Great Value, Walmart) by gavage and
sacrificed 3 hours after the gavage. In TNFα administration experiment, both WT and CREBH
KO mice were divided into two groups and then mice were fasted overnight for 13 hours with
free access to water. One group was treated with recombinant human TNFα (), and the other
group (control) was treated with saline. TNFα was injected ip at 0.001mg/kg, and the controls
received the same volume of saline at the same time of day. After treatment for 5 hours, all the
mice were killed. At the moment of sacrifice, mice were anesthetized under isoflurane and blood
was directly collected from the heart. Blood samples were collected in heparin coated capillary
tubes and centrifuged at 3000 rpm for 30 min and stored at −80°C for further analysis. Tissues,
including liver, intestine, and adipose tissue, were collected, resected, and snap-frozen in liquid
nitrogen and stored at −80°C for further analysis. Liver and intestinal tissues were then analyzed
by quantitative reverse-transcription polymerase chain reaction (PCR), real-time PCR and
immunoblots analyses. All protocols for animal care and experiments were approved by the
Ethical Committee of University of Nebraska- Lincoln.
3. Immunoblots analysis
Following treatment, media was collected and cells were washed with ice-cold 1x PBS, rinsed
totally three times, then lysed in solubilising buffer consisting of 150 mM sodium chloride (NaCl)
(Sigma-Aldrich Canada Ltd., Oakville, ON), 10 mM tris (hydroxymethyl) aminomethane (Tris)
(pH 7.4) (Bio-Rad Laboratories Ltd., Mississauga, ON), 1 mM ethylenediaminetetraacetic acid
(EDTA) (Sigma-Aldrich Canada Ltd., Oakville, ON), 1% Nonidet P-40 (Sigma-Aldrich Canada
Ltd., Oakville, ON), and protease inhibitor cocktail tablet (Roche Applied Science, Laval, QC.).
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Cells were then scraped and passed through a 23G needle 5 times. Cell lysates were centrifuged
in a Heraeus Biofuge Pico centrifuge (Thermo Electron Corporation Canada, Gormley, ON) at
13,000 rpm for 15 minutes, then supernatants were transferred to new microfuge tubes and
mixed with 2X Laemmli sample buffer consisting of 2% sodium dodecylsulfate (SDS) (Bio-Rad
Laboratories Ltd., Mississauga, ON), 20% glycerol (Sigma-Aldrich Canada Ltd., Oakville, ON),
250 mM Tris-HCl, 5% 2-mercaptoethanol (Sigma-Aldrich Canada Ltd., Oakville, ON), and 0.01%
bromophenol blue (BDH Chemicals Ltd., Poole, England). This was followed by boiling for 5
minutes at 100°C. Before further analysis, samples were stored at -80°C for detection of all other
proteins. Media samples were also centrifuged and the supernatants were transferred to new
microfuge tubes before addition of 4X Laemmli sample buffer, boiling for 5 minutes at 100°C
and storage at -80°C.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 15% acrylamide
gels for Histone H3 detection, 6% acrylamide gels for apoB detection, 10% acrylamide gels for
SREBPs, and 12% for all other proteins, with running buffer (25 nM Tris, 192 mM glycine
[Sigma-Aldrich, St. Louis, MO], 0.1% SDS) and a mini-PROTEAN electrophoresis system (BioRad Laboratories Ltd., Mississauga, ON). Gels were transferred onto polyvinylidene fluoride
(PVDF) membranes (PerkinElmer, Woodbridge, ON) with transfer buffer (190 mM glycine, 25
mM Tris, 10% methanol) and a wet transfer apparatus (Bio-Rad Laboratories Ltd., Mississauga,
ON).
Membranes were blocked in either 5% milk (Bio-Rad Laboratories Ltd., Mississauga, ON) in 1x
Tris-buffered saline with tween (TBST; 10 mM Tris, 150 mM NaCl, 0.05% Tween 20 [SigmaAldrich Canada Ltd., Oakville, ON]) or 1% BSA in 1x TBST for at least 2 hours at room
temperature or overnight 4°C, with shaking on an orbital shaker. Membranes were then shaken
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with primary antibodies, diluted 1:1000 in either 5% milk or 2% BSA, overnight at 4°C. The
following antibodies were used: anti-apoB and anti-albumin (Midland Bioproducts, Boone, IA);
anti-β-actin (Sigma-Aldrich, St. Louis, MO); anti-CREBH, anti-SREBP-1, anti-SREBP-2, antiInsig-1, and anti-Insig-2 (Santa Cruz, Dallas, TX); and anti-histone H3 (Thermo Scientific,
Waltham, MA). Membranes were washed 3 times for 5 minutes in 1x TBST, then shaken for 1
hour at room temperature with the appropriate secondary antibody – either donkey anti-rabbit
IgG conjugated to horseradish peroxidase (HRP) (GE Healthcare, Buckinghamshire, UK), sheep
anti-mouse IgG-HRP (GE Healthcare, Buckinghamshire, UK) or rabbit anti-goat IgG-HRP
(Santa Cruz, Dallas, TX). All secondary antibodies were diluted 1:5000. Membranes were
washed 6 times for 5 minutes in 1x TBST then covered with enhanced chemiluminescence
reagents (Amersham Biosciences, Pittsburgh, PA) to expose membranes onto autoradiography
film (Denville Scientific Inc., Metuchen, NJ) using exposure cassettes (Eastman Kodak
Company, Rochester, NY). Film was developed with an SRX-101A film processor (Konica
Minolta Business Solutions (Canada) Ltd., Mississauga, ON) and bands were quantified by
densitometry using Alpha Ease FC 4.0 software (Alpha Innotech, San Leandro, CA).
4. mRNA analysis by real-time PCR
Total RNA from rat liver was extracted using TRIzol (Invitrogen, Carlsbad, CA) and used for the
synthesis of cDNA using a high capacity cDNA reverse transcription kit (Applied Biosystems).
mRNA for relevant genes and 18S rRNA were estimated by quantitative real-time PCR using a
SYBR Green PCR Kit (Applied Biosystems, Carlsbad, CA). Quantitative RT-PCR was
performed with a Prism 7300 Sequence Detecting System (Applied Biosystems, Carlsbad, CA).
The primers used were listed in the Appendix.
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5. Quantification of hepatic TG
Total lipids were extracted from the liver according to the method of Folch, J 83. Briefly, lipids
were extracted from homogenized tissues with chloroform-methanol (2:1, v/v). After
centrifugation, the organic phase was collected, dried under nitrogen, and then dissolved in 1%
Triton X 100 in CHCl3. Aliquots were assayed for triglyceride and cholesterol levels using a
colorimetric TG and Cholesterol assay kit (Pointe Scientific Inc.).

6. Statistical analysis
In all cases, at least three independent experiments were performed and the data are presented as
the mean ± standard error of the mean for triplicates within one representative experiment. If a
representative experiment is shown, all three experiments showed similar results. For pairwise
comparisons, the student t-test was used. Probability values of less than 0.05 are considered
statistically significant and are indicated with a single asterisk (*). Likewise, probability values
less than 0.01 are indicated with two asterisks (**).
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Chapter Three
Results
Part 1
Determine the impact of CREBH signaling via insig 2a on hepatic lipogenesis and
systemic hyperlipidemia
Previous studies have shown that CREBH, a liver-enriched ER-bound transcription factor, is
highly involved in glucose and lipid metabolism. Specifically, both full-length CREBH
(CREBH-F) and nuclear CREBH (CREBH-N) could enhance production of the cytosolic
isoform of phosphoenolpyruvate carboxykinase promoter activity in hepatic cells and further
delineate its physiological relevance in gluconeogenesis. To further confirm the potential
involvement of CREBH in hepatic gluconeogenesis, we measured its expression levels in
C57BL/6J mouse liver.
Interestingly, CREBH expression was significantly induced during fasting and was reduced upon
refeeding, a characteristic regulatory pattern known for genes involved in gluconeogenesis (Fig.
1a). Furthermore, mRNA levels for hepatic CREBH (Fig. 1b) confirmed this phenomenon,
showing a strong correlation between CREBH expression and gluconeogenic potential in liver.
Indeed, we observed increased appearance of both full-length and nuclear CREBH under fasting,
confirming that CREBH could be involved in the transcriptional process of hepatic
gluconeogenesis.
Additionally, to further verify the regulation of the two Insigs transcripts by insulin, we also
detected the expression of Insigs in this fasting or refeeding experiment. It is well known that
food consumption can regulate hepatic lipid synthesis and fasting can decrease the synthesis of
cholesterol as well as FA. As discussed before, when insulin is reduced upon fasting, Insig-1
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expression decreases while Insig-2 expression increases. Consistent with previous studies, the
protein expression of Insig-2 was significantly diminished by refeeding animals, whereas Insig-1
protein expression increased dramatically after refeeding (Fig. 3a). In summary, Insig-2 and
Insig-1 protein expressions appear to be inversely regulated in the liver of mice subjected to
fasting and refeeding. Furthermore, both hepatic Insig-1 mRNA and protein were simultaneously
increased in the refed mice compared to the fasted mice (Fig. 3b). However, though Insig-2a
mRNA was decreased significantly by refeeding, Insig-2b mRNA was unaffected (Fig. 3b). This
phenomenon is consistent with the fact that Insig-2a is highly and specifically expressed in
hepatocytes while Insig-1 is ubiquitously expressed. At the same time, we found that SCAP
mRNA levels were significantly increased under refeeding conditions (Fig. 3b).
To identify a mechanism for CREBH regulation, we cultured HepG2 cells in media without FBS
in order to mimic fasting signaling. Under refed conditions, protein expressions of both the fulllength and nuclear forms of CREBH were decreased significantly (Fig. 4), suggesting an
involvement of CREBH in the process of fasting signaling.
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Fig.3. CREBH and Insigs expression in C57BL/6J mouse liver under fasting and refeeding
conditions. (A) WT mice were divided into fasted and refed groups. The fasted group was fasted
13 hours with free access to water and anesthetized under isoflurane. At the same time, the refed
group was also fasted for 13 hours with free access to water and then fed an ad libitum diet for 8
hours before sacrifice. After sacrifice, liver extracts were assayed by immunoblotting for the
membrane-bound precursor (CREBH-F) and mature nuclear (CREBH-N) forms of CREBH, as
well as Insig-1 and Insig-2. (B) Blots are representative of three independent experiments. Both
CREBH and Insigs bands were quantified by densitometry and intensities are shown relative to
the loading control, β-actin. (C) Relative mRNA levels of hepatic CREBH, Insig-1, Insig-2a,
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Insig-2b, and SCAP were measured using real-time RT-PCR. Data were expressed as means ±
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Fig.4. CREBH expression is induced during fasting in HepG2 cells. HepG2 cells were fasted by
culturing cells without FBS for 18 hours and refed by culturing in normal media with 5% FBS
for 8 hours, after which cells were lysed and assayed by immunoblotting for the membranebound precursor (CREBH-F) and mature nuclear (CREBH-N) forms of CREBH, Insig-1 and
Insig-2. Insig-1 and Insig-2 showed no significant changes (data not shown). Data were
expressed as means ± SEM (n = 6), *P < 0.05, **P < 0.01.
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The results of Fig. 3 and 4 suggested strongly that both CREBH and Insigs could be greatly
influenced by fasting. To further test this hypothesis in vivo, both WT and CREBH KO mice
were subjected to a fasting and refeeding protocol. Hepatic Insig-1 mRNA levels in both WT and
CREBH KO mice were simultaneously increased under refeeding conditions, whereas Insig-2b
was unaffected (Fig. 5). Specifically, Insig-2a mRNA was decreased by refeeding in WT and
CREBH KO mice, and CREBH KO mice showed significant difference both in fasted and refed
conditions compared to WT mice. This phenomenon was in accordance with the fact that Insig2a is highly and specifically expressed in hepatocytes whereas Insig-2b is ubiquitously expressed.
At the same time, we found that SCAP mRNA levels were increased under refed conditions in
WT mice, although the difference did not reach statistical significance in CREBH KO mice.
SCAP protein levels were consistent with the mRNA results (Data not shown). These data
demonstrated that Insig-2a expression could be specifically regulated by both CREBH and
insulin levels while not Insig-2b.
Activation of Insig-1 and Insig-2a signaling upon exposure to fasting and refeeding urged us to
further investigate de novo lipid synthesis pathways in CREBH KO mice. Previous studies had
shown that CREBH is a key metabolic regulator of hepatic lipogenesis, FA oxidation, and
lipolysis under metabolic stress; after feeding an atherogenic high-fat diet, compared to control
mice, a massive accumulation of hepatic lipid metabolites and a significant increase in plasma
TG levels were observed in CREBH KO mice50. We first determined whether SREBPs activation
level was higher in CREBH KO mice since SREBP-1 directly regulates free FA synthesis in the
liver. Indeed, expression of full-length SREBP-1c precursor (SREBP-1c-p) protein was markedly
increased in CREBH KO mice (Figure 6A). Concurrently, the active nuclear form of SREBP-2
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(SREBP-2-n), which regulates cholesterol metabolism, was significantly induced upon refeeding
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treatment in CREBH KO mice (Figure 6A).

Fig.5. Inverse changes in Insig-2a and Insig-1 in the liver of mice subjected to fasting and
refeeding. WT and CREBH KO mice were divided into fasted and refed groups. The fasted
group was fasted 13 hours with free access to water and sacrificed under isoflurane. At the same
time, the refed group was also fasted for 13 hours with free access to water and then fed an ad
libitum diet for 8 hours before sacrifice. Finally, total RNA from liver samples was pooled and
subjected to real-time PCR quantification. Data were expressed as means ± SEM (n = 3), *P <
0.05, **P < 0.01.
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Fig.6. Refeeding induces hepatic full-length and nuclear SREBP protein expression and mRNA
levels in both WT and CREBH KO mice. WT and CREBH KO mice were divided into fasted
and refed groups. WT and CREBH KO mice were divided into fasted and refed groups. The
fasted group was fasted 13 hours with free access to water and anesthetized under isoflurane. At
the same time, the refed group was also fasted for 13 hours with free access to water and then fed
an ad libitum diet for 8 hours before sacrifice. (A) Protein masses of precursor (p) and nuclear (n)
SREBP-1c as well as nuclear SREBP-2 were detected by immunoblots analysis of cell lysates.
(B) Immunoblots were quantified by densitometry and precursor proteins were normalized to βactin, while nuclear proteins were normalized to Histone H3. (C) Total RNA was extracted from
liver tissues to detect mRNA expression of SREBP-1c as well SREBP-2. Results are shown as
means ± SD for two experiments that were performed in triplicate and n of 3 per group for
animal study. *P<0.05.
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To further explore the foundations of lipogenesis in WT and CREBH KO mice when they were
exposed to fasting and refeeding situations, we measured the mRNAs of a number of SREBP-1c
target genes that are involved in hepatic de novo FA synthesis, including FA synthase (FASN),
acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase-1 (SCD-1). Consistent with the
activation of SREBP-1c upon refeeding, transcription of FASN, ACC, and SCD-1 mRNAs was
significantly increased in CREBH KO mice compared to WT mice (Figure 7A). In parallel to the
effects on mRNA expression of SREBP-1c target genes, we also observed the same increase in
SREBP-2 target genes, including Hydroxymethylglutaryl Coenzyme A Synthase (HMGCS),
HMG-CoA reductase (HMGCR), and LDL receptor (LDLR) (Figure 7B). Synthesis of
triglyceride is a fundamental biochemical pathway, essential for nutrient utilization and energy
storage. The enzyme catalyzing the final and committed step in the triglyceride biosynthetic
pathway is diacylglycerol acyltransferase (DGAT). DGAT1 and DGAT2 are two of the several
enzymes with DGAT activity that were cloned and characterized at the molecular level.
Specifically, DGAT2 has been identified as the enzyme that catalyzes the de novo synthesis of
triacylglycerols from newly synthesized FA and nascent diacylglycerols. DGAT levels were
detected and remained unchanged between different groups (Figure 7C).
Glucose homeostasis is tightly regulated to meet fuel requirement in mammals. During fasting,
secretion of pancreatic hormone, glucagon, adrenal hormone, and glucocorticoid is induced to
enhance hepatic glucose production. Previous studies demonstrated that this process is partly
accomplished through activation of gluconeogenesis, resulting from the transcriptional activation
of gluconeogenic genes such as the cytosolic isoform of phosphoenolpyruvate carboxykinase or
glucose-6-phosphatase. Additionally, cAMP response element has been found in gluconeogenic
gene promoters, underscoring the importance of these transcriptional machineries in this pathway.
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When HepG2 cells were exposed to glucagon treatment, both protein and mRNA levels of
CREBH were increased. In the presence of glucagon, expression of full-length CREBH was
slightly increased, but not to a level that was statistically significant (Figure 8). Subsequently, we
confirmed that Insig-2 expression was also increased accordingly. However, Insig-1 protein and
mRNA showed no changes, which were in accordance with the former results.
Previous studies demonstrated that CREBH is nutritionally regulated and activated by FA and
PPAR alpha. To identify a novel mechanism for CREBH regulation, we treated HepG2 cells
with stimuli known to mimic fasting signals, particularly forskolin. Forskolin is a cAMP agonist
that can significantly enhance both mRNA and protein levels of CREBH. Of interest, when
CREBH expression was increased, Insig-2a mRNA levels increased accordingly. The increase in
Insig-2a mRNA translated into a significant increase in Insig-2 protein (Figure 9). Surprisingly,
this was not the case with Insig-1, as we failed to show a change in Insig-1 protein mass or
mRNA (Figure 9). This may be due to the rapid degradation of Insig-1 protein. These results
suggested that CREBH might regulate Insig-2a when CREBH was induced by Glucagon. Indeed,
a chromatin immunoprecipitation (ChIP) assay further confirmed the physical association
between CREBH and the Insig-2a promoter (data from Dr. Wang Hai, not shown). These data
identified Insig-2a as a target gene of CREBH.
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Fig.7. mRNA levels of SREBP target genes in both WT and CREBH KO mice under fasting and
refeeding conditions. (A) Total RNA was extracted to detect mRNA expression of SREBP-1
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target genes, FASN, ACC, and SCD-1 reductase. Transcript levels were normalized to internal
control 18S ribosomal RAN. (B) The mRNA expressions of SREBP-2 target genes, HMGCS,
HMGCR, and LDLR, were also investigated. Transcript levels were also normalized to internal
control 18S ribosomal RAN. (C) The mRNA expressions of DGAT1 and DGAT2 were also
examined. Results are shown as means ± SD for one representative experiment performed in
triplicate. Three experiments were performed in triplicate and showed similar results. *P<0.05,
**P<0.01.
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Fig.8. The regulatory role of glucagon-induced expression of CREBH. (A) HepG2 cells were
cultured without FBS overnight, and then treated with 1ng/ml glucagon for 12 hours. Both
mRNA and proteins were collected for further analysis. (B) Immunoblots were quantified by
densitometry and CREBH precursor protein was normalized to β-actin. (C) mRNA levels of
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Fig.9. The regulatory role of forskolin-induced expression of CREBH. HepG2 cells were
cultured without FBS overnight, and then treated with 10 µM forskolin 12 hours. Both mRNA
and protein were collected for further analysis. (B) Immunoblots were quantified by
densitometry and all proteins were normalized to β-actin. (C) mRNA levels of CREBH, Insig-2a,
and SCAP were also detected. Results are shown as means ± SD for two experiments that were
performed in triplicate. *P<0.05, **P<0.01.
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Part 2
Determine the impact of CREBH on hepatic VLDL assembly and secretion via increased
expression of apoB

ApoB is a key structural protein of VLDL particles produced in the liver, and therefore apoB
levels are an ideal indicator of VLDL production. Perturbation of apoB protein synthesis can
result in either accumulation of lipids in hepatocytes or VLDL overproduction. McA cells were
transfected with the empty vector, CREBH 7.1 and CREBH DN to see their respective roles in
apoB expression. Preliminary studies have demonstrated that depletion of CREBH decreases
apoB mRNA expression (Figure 8B), whereas forced expression of CREBH in McA cells
enhances expression of apoB at the transcriptional and translational levels (Figures 10B and C).
These data indicated that the abundance of CREBH can influence apoB expression.
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Fig.10. Forced expression of CREBH in McA cells induces mRNA and protein expressions of
ApoB. McA cells were seeded onto 6-well plates, and then transfected with 2 ug plasmids. M
were transfected with 2 μg empty DNA vector p3×FLAG-CMV7.1 (Vector), vector expressing
the active nuclear form of CREBH (CREBH 7.1) or vector expressing only the CREBH bZIP
domain (CREBH dominant negative domain, CREBH DN), respectively. Five hours after
transfection, cells and media were collected for protein and mRNA analysis. (A) A
representative western blot analysis showing the protein levels of CREBH in transfected McA
cells. (B) Transfection efficiency was further shown by polymerase chain reaction. (C) After
transfection, the apoB expression was detected in media.
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ApoB is required for VLDL formation and hence influences lipid transportation out of the liver.
Firstly, in order to test if CREBH posed an influence on apoB and VLDL formation, we treated
both WT and CREBH KO mice with virgin olive oil by gavage after 5 hours fasting. In order to
eliminate the influence of LPL, we treated mice with LPL inhibitor Poloxamer before gavage.
Plasma apoB levels were obviously lower in CREBH KO mice, relative to WT mice, suggesting
a regulatory role for CREBH in apoB expression (Figure 11).

Fig.11. ApoB expression in mice after gavage administration of fat in the form of virgin olive oil.
In Olive oil gavage treatment, all mice were firstly fasted overnight for 5 hours with free access
to water, followed a baseline fasting blood sample was collected and Poloxamer 407 was
administrated 2.5ul/g by ip injection. Finally, both WT and CREBH KO mice were fed 200µl
virgin olive oil (Great Value, Walmart) by gavage and sacrificed 3 hours after the gavage, and
blood were collected again. (A) WT and CREBH KO mice (WT, n=6; KO MICE, n=4) were
fasted for 5 hours. Basal line blood was collected, and apoB immunoblots were performed on
plasma. (b) Mice were subjected to oral gavage with virgin olive oil. Blood was collected 3 hours
after gavage, and apoB immunoblots were performed on plasma.
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To further assess the potential involvement of CREBH in hepatic apoB expression in the liver,
we treated both WT and CREBH KO mice with TNFα. As discussed before, TNFα can prompt
CREBH mRNA expression, and TNFα treatment in animal experiments can directly stimulate
hepatic assembly and secretion of VLDL. After fasting for 13 hours, both the WT and CREBH
KO mice were treated with saline or TNFα. Then both Triglyceride and Cholesterol were
measured from liver tissue. Triglyceride content increased in both WT and CREBH KO mice
after TNFα treatment, though there is no significant difference between the two groups. However,
there is an obviously increase in CREBH KO mice compared with WT mice after TNFα
treatment (Figure 12). These data indicated that TNFα can induce lipids accumulation in the liver,
and there is more lipids appeared in CREBH KO mice compared with WT mice.

Hepatic Triglyceride and Cholesterol (mg/g)
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WT/Saline
WT/TNF
KO/saline
KO/TNF

15
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10

**

5

0
Triglyceride

Cholesterol

Fig.12. Hepatic triglyceride and cholesterol content in both WT and CREBH KO mice treated
with TNFα. All mice were fasted for 13 hours, followed by ip injection of either TNFα or Saline.
Mice were sacrificed 5 hours after treatment and the liver samples were homogenized to detect
lipid contents. Results are shown as means ± SD for two experiments, n=3, *P<0.05, **P<0.01.
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Chapter Four
Discussion
Part 1
Insig-2a Links CREBH Signaling to Hepatic Lipogenesis and Systemic Hyperlipidemia
In the current study, we examined the effects of CREBH on liver lipid metabolic signaling and
regulation of genes involved in hepatic de novo FA synthesis. Initially, CREBH was identified as
a hepatocyte-specific bZIP transcription factor belonging to the CREB/ATF family. CREBH was
also known as a gene whose expression is dependent on hepatocyte nuclear factor 4α, which is
highly involved in initiating and maintaining hepatocyte differentiation and liver function.
Recent studies further demonstrate that CREBH mediates both the regulation of glucose and
lipid metabolism. It has been well-established that secretion of insulin is controlled by nutritional
signaling, such as fasting and refeeding conditions and mRNA expression of Insig-1 and Insig-2
are positively or negatively regulated by insulin, respectively. In addition, Insig-1 itself is a
target of nSREBPs, and its mRNA rises and falls coordinately with nSREBPs levels. Hepatic
Insig-1 protein level was low in the liver after 13 hours fasting, but became strongly induced
after 8 hours of refeeding. On the other hand, Insig-2 is negatively regulated by insulin, though it
is constitutively expressed at a low level in cultured cells. Consistent with our expectation, Insig2 protein level was significantly decreased in the C57BL/6J mice fed a normal chow diet after
13h fasting. Furthermore, hepatic Insig-1 mRNA was simultaneously increased in the refed mice
compared to the fasted mice, while Insig-2a mRNA was decreased significantly by refeeding.
Our data clearly suggest that Insigs can be inversely regulated by insulin. Interestingly, when
CREBH expression was induced by glucagon and cAMP agonist-forskolin in HepG2 cells, both
mRNA and protein levels of Insig-2a expression were upregulated. On the other hand, the

47

expression of Insig-1 remained unchanged even though CREBH was induced. This is might
because Insig-2 is a stable protein, whereas Insig-1 is a short-lived protein. Depletion or
suppression of CREBH expression by refeeding inhibited Insig-2a expression, which in turn
hyperactivated SREBP-1c and -2, leading to the activation of hepatic de novo lipid synthesis,
accumulation of lipids in hepatocytes and systemic hyperlipidemia.
Previous results had shown that CREBH is a key metabolic regulator of lipid homeostasis,
including hepatic lipogenesis, FA oxidation, and lipolysis, under metabolic stress50. SREBPs are
master transcription factors that regulate hepatic de novo lipogenesis and perturbation of
SREBPs function is closely related to the onset of hyperlipidemia. Our study demonstrated that
expression of Insig-2a was significantly decreased in the CREBH KO mice compared to its wild
type littermate which led to the hyperactivation of SREBP-1c and SREBP-2. Consistence with
the aberrant activation of SREBPs in the CREBH KO mice, the downstream target genes which
involved in FA synthesis and lipid metabolism was activated, such as FASN, ACC, SCD-1,
HMGCR, HMGCS, and LDLR. Activation of these genes led to the subsequently activation of
hepatic lipid synthesis and the consequently systemic hyperlipidemia. Specifically, we noticed
that both mRNA and proteins of SREBPs were higher in CREBH KO mice under refeeding
conditions, which indicated that CREBH was essential in lipid metabolism. Our data were
consistent with previous studies that showed massive accumulation of hepatic lipid metabolites
and significant increase in plasma TG levels in CREBH KO mice after feeding an atherogenic
high-fat diet.
Glucagon is a hormone that regulates blood glucose in a manner opposite to that of insulin. In the
present study, we found that when HepG 2 cells were treated with glucagon, both mRNA and
protein levels of CREBH increased significantly along with Insig-2a, while Insig-1 remained
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unchanged. When CREBH expression was increased significantly by forskolin, there was a
corresponding increase in both protein and mRNA levels of Insig-2a. Furthermore, a ChIP assay
showed that there is a CREB binding site in the promoter of the Insig-2a gene, which further
confirmed the physical association between CREBH and Insig-2a. Modulation of Insig-2a
expression by CREBH appears to be essentially involved in regulating hepatic triglyceride
metabolism. Further direct studies of Insig-2a KO mice model will be a good approach to further
investigate this hypothesis.
Part 2
The impact of CREBH on hepatic VLDL assembly and secretion via increased expression
of apoB
To further exploit the regulatory impact of CREBH on lipoprotein metabolism, we investigated
the mechanism through which CREBH regulates apoB biosynthesis and VLDL secretion from
the liver. Recent studies have also demonstrated that TNFα is able to induce ER stress which in
turn activating CREBH. Specifically, TNFα can prompt CREBH mRNA expression in a timedependent manner and increased TNFα also directly stimulate hepatic assembly and secretion of
VLDL. However, whether or not TNFα regulates apoB levels by altering the expression of
CREBH remains unknown. In summary, our aim is to find whether or not TNFα regulates apoB
levels by altering the expression of CREBH. Firstly, we demonstrated that CREBH upregualted
apoB mRNA expression. Forced expression of CREBH increases apoB biosynthesis and VLDL
secretion. Depletion of CREBH compromised VLDL-apoB assembly and secretion which
resulted in the accumulation of lipids in the liver of CREBH-KO mice. Our study provides novel
insights into the duo-role of CREBH in regulating hepatic lipid and lipoprotein metabolism. It
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may land support for developing CREBH as a nutritional target for the prevention and treatment
of hyperlipidemia and obesity.
We will be able to determine whether overexpression of apoB induced by TNFα is capable of
reducing hepatic lipid load to rescue CREBH-null mice from TNFα-induced CREBH expression.
To investigate if overexpression of TNFα will promote the secretion of lipids from hepatocytes,
we will deliver TNFα or saline (as control) into WT/CREBH KO mice via ip injection. Current
in vitro studies shows that forced expression of CREBH can induce apoB expression. On the
other hand, apoB expression decreases when we silence CREBH expression. In animal
experiments, we found that TNFα treatment can induce triglyceride accumulation in the liver.
Further research is necessary to gain more insight into the proposed mechanisms and to achieve a
complete picture of them.
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Contribution to Original Knowledge
CREBH, a recently identified transcription factor, had been shown to play a crucial role in
regulating hepatic lipid homeostasis, including hepatic lipogenesis, fatty acid oxidation, and
lipolysis under metabolic stress conditions50. The candidate’s major contributions are to
demonstrate that CREBH inhibits hepatic de novo lipogenesis by regulating Insig-2a expression.
The candidate further demonstrated that CREBH might be involved in VLDL secretion by
influencing apoB expression. Mutation of CREBH has been reported to be closely associated
with the development of hypertriglyceridemia in human subjects55. Previous findings indicate
that CREBH is a molecular link between lipid homeostasis and inflammation53. This study has
the potential to advance our understanding of the pathogenesis of hyperlipidemia, obesity,
metabolic syndrome and NAFLD, and would provide novel insights into metabolic syndrome
and potentially lead to innovative nutrient-based therapeutic strategies.
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Chapter Six
APPENDIX
List of Primers
Table 3. Primers used for qRT-PCR
GATCCGAGGGCCTCACTAAAC

18s
Insig-1

TAAGTCCCTGCCCTTTGTACACA
Forward

ACACGTGGGACCTAACTTGC

Reverse

TCTGAAATGACCCGAGAACC

Forward

CCCTCAATGAATGTACTGAAGGATT

Reverse

TGTGAAGTGAAGCAGACCAATGT

Forward

GAAGCAGACCAATGTTTCAATGG

Insig-2a

Mouse

Mouse

Insig-2b

Mouse
Reverse

CCGGGCAGAGCTCAGGAT

Forward

CGGAAGCTGTCGGGGTAG

Reverse

GTTGTTGATGAGCTGGAGCA

Forward

GTCTCGGTTCTTCCTGGCTC

Reverse

TCCTTGGCAGAGGTCCAGTA

Forward

GCCTGAGGGAGAAGGTCAAC

Reverse

CTCTCCAGAGGTTTGGGCTG

Forward

AGGCAGCAGTTGAAACCCTA

SREBP-1c

Mouse

SREBP-2

Mouse

FASN

Mouse

ACC

Mouse
Reverse

TGAGCCTTGGTGTCTTCTCC

Forward

GTCTGAACCTGACCCATCCC

Reverse

ATCCATTCCATCAGGGCTGC

Forward

ATTTGCTCACCGTGGAGATGTT

Reverse

GAAGTCATCCAGGCCACTACTAATG

Forward

AGCTTGCCCGAATTGTATGTG

SCD1

Mouse

SCAP
HMGCR

Mouse

Mouse
Mouse
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Reverse

TCTGTTGTGAACCATGTGACTTC

Forward

CCCTCCCTGGGAGATAAAGTG

Reverse

CCCGTGAATTGAAGCTGTCA

Forward

GGGAACATTTCGGGGTCTGT

Reverse

AGTCTTCTGCTGCAACTCCG

Forward

TCAACTACGATGCCCCAGTG

Reverse

GAACTCCAGGCCCAGGTTAG

Forward

GGCTACGTTGGCTGGTAACT

HMGCS

Mouse

LDLR

Mouse

DGAT1

Mouse

DGAT2

Mouse
Reverse

CTTCAGGGTGACTGCGTTCT

Forward

CCTCTGTGACCATAGACCTGG

Reverse

ACGGTGAGATTGCATCGTGG

Forward

AGACAGCATCTTCGTGTTTCAA

Reverse

ATCATTTAGTTTCAGCCCAGGA

Forward

GTGACGCTCTTTCCACCTGA

Reverse

AAAGACTGCTACACACCGCA

Forward

TCGTGTGATGGGTCTCACATC

Reverse

GTCCCAAGGCACTAGATGTTTC

CREBH

Human

apoB100

Human

Insig-1

Human

apoB100

Rat

